Opendata, web and dolomites

BGV1 SIGNED

New vaccine for a paradigm shift in Brucellosis, one of the world’s most widespread zoonotic diseases affecting humans

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BGV1 project word cloud

Explore the words cloud of the BGV1 project. It provides you a very rough idea of what is the project "BGV1" about.

diagnostic    shift    designed    brucella    vaccine    evading    world    paradigm    humans    africa    generate    threats    keepers    livestock    human    candidate    standard    limited    livelihoods    serodiagnostic    efficacy    exhibiting    caused    mass    outbreaks    residual    enhanced    small    brucellosis    greenvac    lives    medicine    first    antibiotics    1950s    benefits    antibiotic    america    environmental    cumulative    protective    rising    overcomes    eradication    2028    treatable    bgv1    impacts    unnecessary    anywhere    animals    mediterranean    prevalent    losses    bioterrorism    lower    serious    severely    successful    incidence    economic    relatively    safe    minimal    lactating    safety    globalisation    science    classic    resistance    profile    mainly    animal    global    endemic    amidst    diagnostics    interference    combined    replace    health    radical    species    integration    vaccination    regions    virulence    avirulent    poor    latin    eliminate    ruminants    rate    veterinary    melitensis    time    suffer    virulent    transmissibility    81bn    drawbacks    disease    asia    zoonotic    tests    vaccines    infection    pregnant    anyone   

Project "BGV1" data sheet

The following table provides information about the project.

Coordinator
BRUCELLA GREEN VAC SL 

Organization address
address: PLAZA LAMITURRI, 10, 1 A
city: MUTILVA
postcode: 31192
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 2˙005˙250 €
 EC max contribution 1˙403˙675 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-SMEInst-2018-2020-3
 Funding Scheme SME-2b
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2022-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRUCELLA GREEN VAC SL ES (MUTILVA) coordinator 1˙403˙675.00

Map

 Project objective

Brucellosis is the world’s most widespread zoonotic disease. It is a global problem but most severely affects poor livestock keepers in the developing world because of its impacts on human and animal health and livelihoods. Brucellosis is endemic in most of Asia, Africa and Latin America and is prevalent in the EU Mediterranean regions. Currently vaccines for Brucellosis, around since the 1950s, suffer from serious safety drawbacks mainly due to residual virulence for animals and humans. Combined with rising antibiotic resistance, their use is relatively limited.

GreenVac is developing BGV1, the first vaccine in over 60 years against Brucella melitensis in small ruminants that overcomes the main drawbacks of existing vaccines. BGV1 has been designed to a) be avirulent for animals, b) eliminate interference with diagnostic tests after vaccination, c) have low potential transmissibility to humans and, d) be treatable with standard antibiotics. BGV1 is a strong candidate to replace the classic virulent vaccine, exhibiting a safe profile with an enhanced protective efficacy, no residual virulence and minimal serodiagnostic interference.

A successful BGV1 EU-project will allow, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. The reduction of B. melitensis outbreaks and infection rate in animals will generate €3.81bn in cumulative economic benefits for users by 2028 by evading unnecessary diagnostics costs and losses caused by the infection. It will lead to a lower disease incidence in humans amidst ever rising globalisation and bioterrorism threats to anyone, anywhere. BGV1 will contribute to the objectives of the One Health Initiative: One World, One Health, One Medicine to improve the lives of all species through the integration of human medicine, veterinary medicine and environmental science.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BGV1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BGV1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More